Clinical trial
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal…
NCT00080977 · Blumenthal Cancer Center at Carolinas Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00080977 |
|---|---|
| Title | High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2 |
| Official title | Treatment of Patients With Metastatic Renal Cell Carcinoma Who Have Failed Low Dose Intensity Interleukin-2 With High-Dose Intravenous Recombinant Interleukin-2 |
| Lead sponsor | Blumenthal Cancer Center at Carolinas Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Start date | Jun 1, 1998 |
| First posted | Apr 8, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: